Cardiovascular risk in testicular cancer survivors treated with chemotherapy: Incidence, significance, and practice implications

Oncology Nursing Forum

Volumn 32, Issue 5, 2005, Pages 1005-1009

  Zoltick, Barbara H ^a   Jacobs, Linda A ^b   Vaughn, David J ^c  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; COMORBIDITY; HEALTH; HEART INFARCTION; HUMAN; INCIDENCE; MALE; METHODOLOGY; MIDDLE AGED; NURSING; ONCOLOGY NURSING; RAYNAUD PHENOMENON; REVIEW; RISK FACTOR; TESTIS TUMOR;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; COMORBIDITY; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ONCOLOGIC NURSING; RAYNAUD DISEASE; RISK FACTORS; TESTICULAR NEOPLASMS; WORLD HEALTH;

EID: 33745334358     PISSN: 0190535X     EISSN: 15380688     Source Type: Journal    
DOI: 10.1188/05.ONF.1005-1012     Document Type: Article

References (19)

1. Berger, C.C., Bokemeyer, C., Schneider, M., Kuczyk, M.A., & Schmoll, H.J. (1995). Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer. European Journal of Cancer, 31A, 2229-2238.
2. Bokemeyer, C., Berger, C.C., Kuczyk, M.A., & Schmoll, H.J. (1996). Evaluation of long-term toxicity after chemotherapy for testicular cancer. Journal of Clinical Oncology, 14, 2923-2932.
3. Bosl, G.J., Leitner, S.P., Atlas, S.A., Sealey, J.E., Preibisz, J.J., & Scheiner, E. (1986). Increased plasma renin and aldosterone in patients treated with cisplatin-based chemotherapy for metastatic germ-cell tumors. Journal of Clinical Oncology, 4, 1684-1689.
4. Boyer, M., Raghavan, D., Harris, P.J., Lietch, J., Bleasel, A., Walsh, J.C., et al. (1990). Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular cancer. Journal of Clinical Oncology, 8, 21-26.
5. Chaudhary, U.B., & Haldas, J.R. (2003). Long-term complications of chemotherapy for germ cell tumours. Drugs, 63, 1565-1577.
6. Dodd, P.M., & Kelly, W.K. (2001). Testicular cancer. In R.E. Lenhard, Jr., R.T. Osteen, & T. Gansler (Eds.), Clinical oncology (1st ed., 419-426). Atlanta, GA: American Cancer Society.
7. Einhorn, L.H. (1981). Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Research, 41(9, Pt. 1), 3275-3280.
8. Gerl, A. (1994). Vascular toxicity associated with chemotherapy for testicular cancer. Anticancer Drugs, 5, 607-614.
9. Hennessy, B., O'Connor, M., & Carney, D.N. (2002). Acute vascular events associated with cisplatin therapy in malignant disease. Irish Medical Journal, 95(5), 145-146, 148.
10. Huddart, R.A., Norman, A., Shahidi, M., Horwich, A., Coward, D., Nicholls, J., et al. (2003). Cardiovascular disease as a long-term complication of treatment for testicular cancer. Journal of Clinical Oncology, 21, 1513-1523.
11. Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R.C., Ghafoor, A., et al. (2005). Cancer statistics, 2005. CA: A Cancer Journal for Clinicians, 55, 10-30.
12. Meinardi, M.T., Gietema, J.A., van der Graaf, W.T., van Veldhuisen, D.J., Runne, M.A., Sluiter, W.J., et al. (2000). Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. Journal of Clinical Oncology, 18, 1725-1732.
13. Meinardi, M.T., Gietema, J.A., van Veldhuisen, D.J., van der Graaf, W.T., de Vries, E.G., & Sleijfer, D.T. (2000). Long-term chemotherapy-related cardiovascular morbidity. Cancer Treatment Reviews, 26, 429-447.
14. National Comprehensive Cancer Network. (2004). Clinical prectice guidelines in oncology: Testicular cancer [Version 1.2004]. Jenkintown, PA: Author.
15. Nord, C., Fossa, S.D., & Egeland, T. (2003). Excessive annual BMI increase after chemotherapy among young survivors of testicular cancer. British Journal of Cancer, 88, 36-41.
16. Raghavan, D., Cox, K., Childs, A., Grygiel, J., & Sullivan, D. (1992). Hypercholesterolemia after chemotherapy for testis cancer. Journal of Clinical Oncology, 10, 1386-1389.
17. Strumberg, D., Brugge, S., Korn, M.W., Koeppen, S., Ranft, J., Scheiber, G., et al. (2002). Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Annals of Oncology, 13, 229-236.
18. Vaughn, D.J., Gignac, G.A., & Meadows, A.T. (2002). Long-term medical care of testicular cancer survivors. Annals of Internal Medicine, 136, 463-470.
19. Vogelzang, N.J., Torkelson, J.L., & Kennedy, B.J. (1985). Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin. Cancer, 56, 2765-2770.